Nezam El-Tayebat Fact CheckA scientific assessment of the “نظام الطيبات” nutrition system
Choose country
Choose language: English

Mostly true True only under certain conditions Certainty of evidence: moderate provisional C-CHM-04

Chemotherapy causes persistent cognitive decline ('chemo fog').

In short: Chemotherapy-related cognitive problems are real and can last at least months, but on average they are small and mostly improve; lasting decline affects a minority.
Conclusion: Chemo-related cognitive effects are real but on average small.
  1. Original statement
  2. Scientific assessment
  3. Scientific evidence in detail
  4. In plain language
  5. Studies on this claim
  6. Regional context
  7. What applies in my country?
  8. References

Original statement

تدهور معرفي مستمر («ضباب الكيماوي»)

not verbatim – paraphrase. Translation by the project; the Arabic wording is authoritative.

Translation

Chemotherapy causes persistent cognitive decline ('chemo fog').

Origin

Source status
Archive editors
Attribution
Archive editors (rule page summary/narrative)
Origin
https://eltayebat.com/rule/chemo-radiation/
Attribution uncertainty
Written by archive operators; not attributed to Elawady.
Claimed mechanism

Neurotoxicity of cytotoxic drugs

Claimed health effect

Cognitive impairment

Population concerned

Breast cancer and lymphoma survivors

Geographic restriction by Elawady

none found

Scientific assessment

Mostly true – Correct at its core, but with limitations or minor inaccuracies.

Certainty of evidence: moderate – Further research may still affect the assessment.

1. What was claimed?

Persistent cognitive decline confirmed by Ahles and Jim.

2. What is demonstrably correct?

Long-term survivors after chemotherapy scored lower on tests, with a subgroup clearly affected (39% vs 14% in lowest quartile; A-CHM-09). A meta-analysis found deficits >=6 months after chemotherapy in verbal (g=-0.19) and visuospatial ability (g=-0.27) (A-CHM-10).

3. What is wrong or exaggerated?

'Persistent cognitive decline' overstates the average: deficits are small and limited to two of eight domains; Ahles et al. note only a subgroup has long-term deficits.

4. What remains unclear?

Who is at risk and whether effects improve over time.

5. Which studies support it?

A-CHM-09, A-CHM-10.

6. Which studies contradict it?

A-CHM-10 (small average magnitude).

7. What applies to Germany and Europe?

Cognitive rehabilitation offers exist in some European survivorship programmes (not audited).

8. What is known about Egypt?

No data reviewed.

9. What practical conclusion is appropriate?

Report thinking or memory problems; most survivors are mildly affected.

Assessment details

Rationale for certainty of evidence

Effect exists in a meta-analysis and earlier studies, but average magnitude is small and limited to some domains; heterogeneous studies.

Source quality

Correctly cited studies; overstated summary.

Regional transferability

High.

Individual exceptions

Subgroup with larger deficits.

Regional scope of the claim
general (biological/medical)
Last reviewed
26 October 2026 provisional

Scientific evidence in detail

True only under certain conditions – The claim holds only for certain doses, groups of people, preparations or circumstances.

Research question: Does chemotherapy cause measurable cognitive decline that persists after treatment, and how large is it?

Research question in detail (PECO)
Population
Cancer patients (mostly breast cancer) treated with chemotherapy
Intervention or exposure
Systemic chemotherapy
Comparison
Patients without chemotherapy; healthy controls; pre-treatment baseline
Geographic scope
universal biology
Outcomes
  • Objective cognitive performance
  • Self-reported cognitive problems
  • Persistence over time

Study results as reported by the authors. Our assessment follows below.

What speaks for the claim?

What speaks against the claim?

What does the overall evidence say?

Editorial assessment based on the studies above – not itself a study result.

Which position is better supported?

Chemotherapy-related cognitive impairment is real; on average it is small, strongest during and soon after treatment, and lasts longer in a subgroup.

Why some studies weigh more

Prospective controlled cohorts outweigh cross-sectional studies; meta-analyses give average size.

Is a causal relationship established? Probable Temporal sequence with baseline and controls; residual confounding by cancer itself, endocrine therapy and distress possible.

Remaining uncertainty

Long-term persistence and who is at risk.

Justified conclusion

Mostly true for a subset; 'persistent decline' overstates the average course.

Why do studies seem to disagree?

Janelsins (decline at 6 months) and Kim (mainly acute) differ in outcome type (objective vs subjective) and time windows; both agree an effect exists.

Does this depend on the country?
General biological effects
Universal.
Eating habits
Not relevant.
Origin of the food
Not relevant.
Contaminants
Not relevant.
National production conditions
Not relevant.
Legal rules
Not relevant.
Actual monitoring data
No monitoring data relevant.

A regional difference that changes the conclusion is not supported by robust data.

Statistical re-check
  • Translate SMD to overlap (Cohen U3) – g -0.19: about 42% of treated score better than the control mean (small); g -0.85 (acute, subjective): about 20% recalculated
Certainty of the overall evidence (GRADE, simplified)
Main outcome
Persistent cognitive impairment after chemotherapy
Starting level
low (observational studies)
Reasons for downgrading
  • inconsistency (domain and time-dependent)
Result
moderate

Simplified assessment by a single reviewer, following the GRADE approach; not a formal GRADE panel. GRADE rates the body of evidence for one outcome, not individual studies.

Search strategy

Documented literature searches for this review (search strings in the original database syntax).

DatabaseDateSearchLooking forHitsIncluded
Europe PMC26 October 2026TITLE:"cognitive" AND (TITLE:"chemotherapy" OR TITLE:"cancer-related") AND (TITLE:"longitudinal" OR TITLE:"nationwide cohort") AND (TITLE:"breast cancer") AND PUB_YEAR:[2015 TO 2026]supporting evidence18
Europe PMC26 October 2026(TITLE:"cognitive" OR TITLE:"cognition") AND TITLE:"chemotherapy" AND (TITLE:"meta-analysis" OR TITLE:"systematic review") AND PUB_YEAR:[2015 TO 2026]both directions44
Europe PMC26 October 2026TITLE:"Longitudinal Trajectory and Characterization of Cancer-Related Cognitive Impairment"supporting evidence1

Open questions

Long-term trajectories beyond 2 years.

How deeply was this checked?

4 linked studies: 0 checked in full text (0 of them with a structured risk-of-bias assessment), 4 on the basis of the abstract, 0 bibliographically only. No formal assessment with two independent reviewers and no independent human expert review has taken place yet.

Last scientific review: 26 October 2026

History of the verdict
  1. 25 October 2026 · Phase 1 · Initial assessment: Mostly true (moderate)
  2. 26 October 2026 · Phase 4 (systematic evidence review) · Re-examined with extended evidence; verdict unchanged: Mostly true (moderate)
    A prospective controlled cohort supports a medium-term effect; a longitudinal meta-analysis supports that it is mostly acute; balance unchanged.
    New sources: I-CHM-111 I-CHM-112

In plain language

Some people notice problems with memory or concentration after chemotherapy. Studies confirm small average differences in some thinking skills, while a minority is more affected. This is real and deserves attention, but it does not mean that everyone has lasting decline.

Studies on this claim

Studies supporting the claim (2)

  • Some long-term survivors show memory problems after chemotherapy

    Ahles TA et al.. J Clin Oncol 2002 · PMID 11786578 · DOI 10.1200/JCO.2002.20.2.485
    Cross-sectional studycited by the Tayebat archiveabstract checked

    39% of chemotherapy-treated vs 14% of locally treated survivors scored in the lowest quarter on memory/thinking tests.

    Cognitive deficits in a subgroup

    Does the study support the specific claim? Partly · Methodological quality: low · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Compare cognition by treatment.

    How was the study done?

    Cross-sectional testing.

    How many people, animals or samples were studied?

    128 survivors (sum of four reported groups: 35+36+35+22).

    What was actually found?

    Lower verbal memory and psychomotor scores.

    How large was the observed effect?

    39% vs 14% lowest quartile.

    What do the results mean in everyday life?

    Some survivors notice thinking problems; support exists.

    What are the study's limitations?

    Small, no baseline.

    What does it say about Elawady's specific claim?

    Supports a subgroup effect.

    Do the results apply to Germany and Europe?

    Moderate.

    What can explicitly not be concluded from this study?

    That all patients suffer lasting decline.

    Scientific details →

  • Memory problems after breast cancer chemotherapy

    Janelsins MC et al.. J Clin Oncol 2018 · PMID 30240328 · DOI 10.1200/JCO.2018.78.6624
    Cohort studyindependent cross-checkabstract checked★ key study

    Patients' memory scores fell during chemotherapy and were still lower 6 months later, unlike controls.

    Cognitive decline measurable 6 months after chemotherapy.

    Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Track thinking skills through chemotherapy

    How was the study done?

    Prospective cohort with controls

    How many people, animals or samples were studied?

    580 patients, 363 controls

    What was actually found?

    Decline persisting at 6 months

    How large was the observed effect?

    P<.005 group-by-time

    What do the results mean in everyday life?

    'Chemo brain' is real for some

    What are the study's limitations?

    Short follow-up; cancer itself may contribute

    What does it say about Elawady's specific claim?

    Supports existence; not 'persistent' long-term

    Do the results apply to Germany and Europe?

    High

    What can explicitly not be concluded from this study?

    Cannot show permanent damage

    Scientific details →

Studies contradicting or limiting the claim (0)

No studies in this group.

Studies with mixed or unclear results (2)

  • Chemotherapy-related thinking problems are small on average

    Jim HS et al.. J Clin Oncol 2012 · PMID 22927526 · DOI 10.1200/JCO.2011.39.5640
    Meta-analysiscited by the Tayebat archiveabstract checked★ key study

    Breast-cancer survivors performed slightly worse in two of eight areas of thinking.

    Small average deficits

    Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Pool studies on cognition after chemo.

    How was the study done?

    Meta-analysis.

    How many people, animals or samples were studied?

    17 studies, 807 patients.

    What was actually found?

    Small deficits in verbal and visuospatial ability.

    How large was the observed effect?

    g -0.19 and -0.27.

    What do the results mean in everyday life?

    Most survivors are only mildly affected, some more.

    What are the study's limitations?

    Heterogeneous studies.

    What does it say about Elawady's specific claim?

    Limits 'persistent decline'.

    Do the results apply to Germany and Europe?

    High.

    What can explicitly not be concluded from this study?

    Individual risk.

    Scientific details →

  • Self-reported thinking problems after chemotherapy

    Kim HJ et al.. Eur J Oncol Nurs 2022 · PMID 35255262 · DOI 10.1016/j.ejon.2022.102099
    Meta-analysisindependent cross-checkabstract checked

    Patients reported more thinking problems mainly in the first month after chemotherapy; the difference was small compared with patients who had no chemotherapy.

    Confirms an association but suggests it is mainly acute and small versus non-chemotherapy patients.

    Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim

    Original publication · Scientific details

    Study explained simply
    What did the researchers want to find out?

    Pool long-term studies

    How was the study done?

    Meta-analysis

    How many people, animals or samples were studied?

    13 studies

    What was actually found?

    Mostly short-term effect

    How large was the observed effect?

    g -0.19 to -0.85

    What do the results mean in everyday life?

    Many people improve after treatment ends

    What are the study's limitations?

    Self-report only

    What does it say about Elawady's specific claim?

    Limits 'persistent'

    Do the results apply to Germany and Europe?

    High

    What can explicitly not be concluded from this study?

    Cannot rule out lasting problems in a subgroup

    Scientific details →

Regional context

Germany / EU

Cognitive rehabilitation offers exist in some European survivorship programmes (not audited).

Egypt

No data reviewed.

What applies in my country?

General scientific assessment

Mostly true Chemo-related cognitive effects are real but on average small.

This statement concerns biological or medical relationships. The scientific assessment above applies regardless of the country; country-specific food data do not change it.

References

  1. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma.. Ahles TA et al.. J Clin Oncol 2002 · PMID 11786578 · DOI 10.1200/JCO.2002.20.2.485
  2. Longitudinal Trajectory and Characterization of Cancer-Related Cognitive Impairment in a Nationwide Cohort Study.. Janelsins MC et al.. J Clin Oncol 2018 · PMID 30240328 · DOI 10.1200/JCO.2018.78.6624
  3. Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy.. Jim HS et al.. J Clin Oncol 2012 · PMID 22927526 · DOI 10.1200/JCO.2011.39.5640
  4. Association of chemotherapy and subjective cognitive impairment in breast cancer patients: Meta-analysis of longitudinal prospective cohort studies.. Kim HJ et al.. Eur J Oncol Nurs 2022 · PMID 35255262 · DOI 10.1016/j.ejon.2022.102099

← Back to overview